ARAF siRNA – Serine/Threonine-Protein Kinase A-Raf Isoform 2 (Human)

ARAF: a tyrosine kinase-like kinase of the RAF family. Involved in the transduction of mitogenic signals from the cell membrane to the nucleus. May play a role in the postsynaptic responses of hippocampal neuron. Frequently mutated in thyroid cancers, skin melanomas and at lower frequency in a wide range of human cancers. An activating mutation, mimicking phosphorylation of the activation loop, is seen in 60% of malignant melanoma samples. Raf mutations are generally exclusive to Ras activating mutations. Activating mutations are also seen in ~10% of colorectal cancers, in lung cancers and gliomas, and at a lower rate in several other tumors. Inactivating mutations are also seen and may result in activation of c-Raf and Erk. Mutations in B-Raf, MEK1 and MEK2 also associated with cardiofaciocutaneous syndrome, displaying morphological, cardiac and mental defects. Approved Inhibitor: Nexavar/Sorafenib.

Protein type: Protein kinase, Ser/Thr (non-receptor); EC 2.7.11.1; Protein kinase, TKL; Kinase, protein; Oncoprotein; TKL group; RAF family

Chromosomal Location of Human Ortholog: Xp11.4-p11.2

Molecular Function: protein serine/threonine kinase activity; protein binding; metal ion binding; receptor signaling protein activity; ATP binding; protein kinase activity

Biological Process: regulation of proteasomal ubiquitin-dependent protein catabolic process; protein modification process; protein amino acid phosphorylation; positive regulation of peptidyl-serine phosphorylation; regulation of TOR signaling pathway; negative regulation of apoptosis